Kytopen & TQ Therapeutics forge partnership to advance next-generation cell therapies
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Now a test that offers new precision in prostate cancer detection
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The fresh capital will propel Cordance into its first-in-human clinical trial
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Subscribe To Our Newsletter & Stay Updated